Felipe Rey

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 254 citations · Full text

Medicine, Oncology, Pharmacology +11

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu et al. · The Lancet Oncology · 2023 · 204 citations

Medicine, Oncology, Pharmacotherapy +12

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin et al. · Journal of Clinical Oncology · 2023 · 132 citations · Full text

Medicine, Oncology, Pharmacotherapy +17